AI-Powered Breast Ultrasound Market Size, Trends & Growth Opportunity By Product Type, By AI Functionality, By End User, By Regulatory Classification, By Region and Forecast Till 2030

Report ID : AMR1006163 | Industries : Healthcare | Published On :September 2026 | Page Count : 216

Request Sample
Ask for Customization

The global AI-powered breast ultrasound market covers automated, handheld, cart-based, portable and cloud-connected breast ultrasound systems that incorporate artificial intelligence software, together with the AI functionality layered onto those systems and platforms, supplied across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

AI-powered breast ultrasound describes a category of imaging hardware and diagnostic software sold as a market segment, and this report makes no claim about the diagnostic accuracy, clinical effectiveness, or comparative performance of any product, software function, or company described on these pages.

Nine segmentation dimensions appear in this report, and the first two describe the product type supplied and the technology architecture it is deployed on.

Product type spans five categories, from automated breast ultrasound systems (ABUS) and handheld AI-enabled breast ultrasound systems through cart-based AI breast ultrasound platforms to portable breast ultrasound systems and cloud-connected breast ultrasound solutions.

Technology architecture covers three categories, embedded AI systems, cloud-based AI platforms, and hybrid AI deployment models, and this pairing determines how a system integrates into an existing radiology or point-of-care workflow.

AI functionality spans seven categories, including computer-aided detection (CADe), computer-aided diagnosis (CADx), lesion segmentation algorithms, breast density assessment software, risk prediction algorithms, workflow optimization software, and automated reporting solutions.

Imaging workflow covers five categories, screening applications, diagnostic applications, follow-up monitoring, treatment response assessment, and interventional guidance, and this dimension determines which AI functionality categories are relevant to a given care episode.

End user spans six categories, hospitals, cancer centers, women's health clinics, diagnostic imaging centers, ambulatory care centers, and academic research institutions, while breast density category covers dense breast screening, non-dense breast screening, and high-risk population screening.

Patient age group spans four categories, below 40 years, 40 to 49 years, 50 to 64 years, and 65 plus years, and procurement model covers direct equipment purchase, AI software subscription, imaging-as-a-service, and enterprise imaging contracts.

Regulatory classification completes the segmentation across five categories, FDA-cleared solutions, CE-marked solutions, NMPA approved solutions, PMDA approved solutions, and other national regulatory approvals, each named here strictly as a market-access category.

This report covers AI-powered breast ultrasound hardware, software, and platforms supplied across the twenty countries named in its geographic scope.

It excludes conventional breast ultrasound systems without AI functionality, general-purpose ultrasound systems not marketed for breast imaging, and mammography or breast MRI systems outside this report's breast ultrasound scope.

Buyer intelligence in the full report maps radiology directors, breast imaging specialists, hospital procurement teams, clinical engineering teams, and CIO and digital health teams across enterprise hospital networks, regional health systems, independent imaging centers, and specialty women's health providers, including a dedicated strategic implications assessment for CHISON.

Competitive benchmarking compares suppliers across estimated market position, distribution reach, service infrastructure, installed base, regulatory approval breadth, and innovation and clinical validation benchmarking, without disclosing proprietary competitive positioning data.

Market Size & Growth Forecast (2026 to 2030)

The global AI-powered breast ultrasound market is estimated at approximately USD 3.3 Billion in 2025 and is projected to reach approximately USD 6.2 Billion by 2030, expanding at a compound annual growth rate of roughly 13.5 percent.

The estimate covers AI-powered breast ultrasound hardware, software, and platforms as defined in the overview above, and excludes conventional non-AI breast ultrasound systems and mammography or breast MRI systems.

Automated breast ultrasound systems (ABUS) account for the largest product type category by revenue, while handheld AI-enabled breast ultrasound systems form the fastest-growing product type category, reflecting expanding point-of-care and decentralised screening use.

Computer-aided detection (CADe) accounts for the largest AI functionality category by installed base, while risk prediction algorithms form a fast-growing functionality category tied to expanding high-risk screening programmes.

Embedded AI systems account for the largest technology architecture category, and cloud-based AI platforms form the fastest-growing architecture category as imaging providers favour software that updates independently of the underlying hardware.

Screening applications account for the largest imaging workflow category by volume, while follow-up monitoring forms a fast-growing workflow category tied to expanding surveillance protocols for previously screened patients.

Hospitals account for the largest end-user category by revenue, and ambulatory care centers form a fast-growing end-user category as AI-enabled portable systems extend breast ultrasound capability beyond fixed imaging departments.

Dense breast screening accounts for the largest breast density category, reflecting the growing number of jurisdictions with dense-breast notification requirements, while high-risk population screening forms a fast-growing category.

Direct equipment purchase accounts for the largest procurement model by installed base, and AI software subscription forms the fastest-growing procurement category as providers separate software licensing from hardware acquisition.

FDA-cleared solutions account for the largest regulatory classification category by revenue, and NMPA approved solutions form a fast-growing category tied to expanding domestic AI imaging clearance activity in China.

North America accounts for the largest regional concentration in this report, and Asia-Pacific forms the fastest-growing region, tied to hospital network expansion and rising screening programme investment across the region's larger economies.

The forecast assumes continued global expansion of breast cancer screening programmes and continued regulatory clearance activity for AI-enabled detection, diagnosis, and workflow software, and a material slowdown in either trend would move the trajectory.

MetricValue
Market Size (2025)Approximately USD 3.3 Billion
Forecast Size (2030)Approximately USD 6.2 Billion
CAGR (2025-2030)Approximately 13.5%
Base Year2025
Forecast Period2026-2030 (5-year)
Scope NoteAI-powered breast ultrasound hardware, software and platforms only; excludes conventional non-AI breast ultrasound and mammography or breast MRI systems
Largest Product CategoryAutomated Breast Ultrasound Systems (ABUS)
Fastest-Growing Product CategoryHandheld AI-Enabled Breast Ultrasound Systems
Largest End-User CategoryHospitals
Fastest-Growing End-User CategoryAmbulatory Care Centers
Largest Regulatory CategoryFDA-Cleared Solutions
Largest Regional ConcentrationNorth America

 

Market Drivers

Expanding breast cancer screening programmes worldwide, including a growing number of jurisdictions with dense-breast notification laws, are routing more women toward supplemental breast ultrasound examinations each year.

Regulatory clearances for AI-enabled detection, diagnosis, and workflow software from FDA, CE, NMPA, and PMDA authorities are widening the pool of solutions that hospitals and imaging centers can adopt.

Persistent radiologist and sonographer workload pressure is pushing hospitals and imaging centers toward workflow optimization and automated reporting software that shortens per-case review time.

Growing adoption of cloud-connected and subscription-based AI software models is lowering the upfront capital barrier for independent imaging centers and regional health systems that previously could not justify a full capital equipment purchase.

Rising installed bases of conventional breast ultrasound hardware create an addressable upgrade opportunity for AI software layered onto existing systems through embedded or hybrid deployment models.

Market Restraints

Reimbursement pathways for AI-assisted breast ultrasound interpretation remain uneven across countries, which slows purchasing decisions at budget-constrained hospitals and independent imaging centers.

Data privacy and cybersecurity requirements for cloud-based AI platforms add compliance overhead that can lengthen hospital procurement cycles, particularly for enterprise hospital networks managing multi-site deployments.

Multiple overlapping regulatory approval pathways, FDA, CE, NMPA, PMDA, and other national frameworks, require vendors to pursue separate certification efforts before entering each market, slowing the pace of new-market entry.

PROCUREMENT INSIGHT

Enterprise hospital networks weighing a multi-site AI software deployment increasingly factor data residency and cybersecurity compliance timelines into the procurement schedule as heavily as the software's regulatory clearance status itself, extending typical evaluation cycles for cloud-based platforms relative to embedded, on-premise deployments.

 

Market Opportunities

Underserved screening populations in emerging markets represent a meaningful opportunity, where portable and handheld AI-enabled systems can extend breast ultrasound access beyond fixed imaging centers into regional and rural facilities.

Integration of breast density assessment and risk prediction software into standard screening workflows opens a software attach-rate opportunity alongside existing hardware installations, independent of any new hardware purchase cycle.

Imaging-as-a-service and enterprise imaging contract models give ambulatory care centers and academic research institutions a lower-friction path to AI-enabled capability without the balance-sheet commitment of a direct equipment purchase.

MARKET SHIFT

Software-only revenue, subscription-based AI functionality layered onto ultrasound hardware a provider already owns, is emerging as a distinct commercial track from the hardware sale itself, a structural shift that increasingly separates a vendor's hardware installed base from its software attach rate as two separate growth metrics.

 

Product Types and Technology Architecture

Automated, handheld, cart-based, portable, and cloud-connected breast ultrasound systems are deployed on embedded, cloud-based, or hybrid AI architectures, and a closer look at product types and technology architecture shows why deployment architecture, not product type category alone, is generally the first integration decision a buying site makes.

AI Functionality and Imaging Workflow Applications

Computer-aided detection, computer-aided diagnosis, lesion segmentation, breast density assessment, risk prediction, workflow optimization, and automated reporting software each map to specific stages of the imaging workflow, and this report's AI functionality and imaging workflow analysis breaks down which capability applies to screening, diagnostic, follow-up, treatment response, and interventional applications.

End Users and Screening Populations

Hospitals, cancer centers, women's health clinics, diagnostic imaging centers, ambulatory care centers, and academic research institutions each serve a different mix of dense breast, non-dense breast, and high-risk population screening, and the end users and screening populations breakdown explains how care setting shapes which population a given site is actually equipped to serve.

Regulatory Classification and Procurement Models

FDA-cleared, CE-marked, NMPA approved, and PMDA approved solutions are procured through direct equipment purchase, AI software subscription, imaging-as-a-service, and enterprise imaging contract models, and the regulatory classification and procurement models page covers how a solution's regulatory status in a given jurisdiction generally gates which of these commercial models is actually available there.

AI-Powered Breast Ultrasound Market, By Region

North America, comprising the United States and Canada, leads global demand, supported by dense-breast notification legislation across a growing number of states and an established hospital network purchasing base.

Europe spans Germany, the United Kingdom, France, Italy, Spain, and the Netherlands, where organised national and regional screening programmes provide a stable institutional demand base for AI-powered breast ultrasound adoption.

Asia-Pacific covers China, Japan, South Korea, India, and Australia, combining rapid hospital network expansion in China and India with earlier AI adoption in South Korea's diagnostic imaging center base.

Latin America includes Brazil, Mexico, and Argentina, where private hospital network demand is the primary near-term adoption driver ahead of broader public-sector screening programme expansion.

The Middle East and Africa spans Saudi Arabia, the United Arab Emirates, South Africa, and Egypt, where national screening programme investment and private hospital network modernisation are the two main adoption pathways.

REGIONAL OPPORTUNITY

Asia-Pacific's combination of large under-screened populations and a fast-expanding private hospital network base makes it the region where portable and cloud-connected product architectures, rather than fixed cart-based platforms, are most likely to carry a disproportionate share of new AI-powered breast ultrasound installations through 2030.

 

Leading Companies

CHISON, GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems, FUJIFILM Healthcare, Samsung Medison, Hologic, Delphinus Medical Technologies, iSono Health, QView Medical, Koios Medical, ScreenPoint Medical, DeepHealth, Clarius, and Butterfly Network are covered in the full report. An introduction to the supplier landscape by company type is available on the leading AI-powered breast ultrasound companies page.

Beyond This Page

The full AI-powered breast ultrasound market report adds regional and country-level sizing across all twenty countries in this report's geographic scope, segment-level share breakdowns for each of the nine segmentation dimensions, and company-level competitive benchmarking not published on this website.

It also includes the complete buyer intelligence assessment, covering procurement models, buying triggers, decision-maker mapping, budget ownership analysis, vendor evaluation criteria, contract value bands, sales cycle analysis, and a dedicated strategic implications assessment for CHISON.

The full report covers each of the sixteen company profiles across corporate overview, geographic footprint, product and service portfolio, target customer segments, distribution and go-to-market strategy, key financials, certifications and regulatory approvals, partnerships and alliances, R&D and innovation strategy, recent developments, and a SWOT snapshot.

Market playbook, pricing and procurement intelligence, go-to-market strategy, and strategic recommendations chapters provide additional depth beyond what is published on this website.

Frequently Asked Questions

The market is estimated at approximately USD 3.3 Billion in 2025 and is projected to reach approximately USD 6.2 Billion by 2030, expanding at a compound annual growth rate of roughly 13.5 percent.

A category of imaging hardware and diagnostic software, spanning automated, handheld, cart-based, portable, and cloud-connected breast ultrasound systems that incorporate artificial intelligence functionality. This report describes the category strictly as a market segment.

Automated breast ultrasound systems (ABUS) account for the largest product type category by revenue, while handheld AI-enabled breast ultrasound systems form the fastest-growing product type category.

Seven categories: computer-aided detection (CADe), computer-aided diagnosis (CADx), lesion segmentation algorithms, breast density assessment software, risk prediction algorithms, workflow optimization software, and automated reporting solutions.

North America accounts for the largest regional concentration, while Asia-Pacific is the fastest-growing region, tied to hospital network expansion and rising screening programme investment.

Sixteen companies are covered in the full report, including CHISON, GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems, FUJIFILM Healthcare, Samsung Medison, Hologic, and several dedicated AI breast imaging software specialists.

Four models: direct equipment purchase, AI software subscription, imaging-as-a-service, and enterprise imaging contracts. Direct equipment purchase accounts for the largest installed base, while AI software subscription is the fastest-growing model.

Five categories: FDA-cleared, CE-marked, NMPA approved, PMDA approved, and other national regulatory approvals, each named in this report strictly as a market-access category.

No. This report describes AI-powered breast ultrasound strictly as a market and product category. It makes no claim about diagnostic accuracy, clinical effectiveness, or comparative performance for any product, software function, or company.

Inquire Before Buying Request Free Sample Ask For Discount

1. Introduction

1.1. Objective of the Study

1.2. Market Definition

1.3. Market Scope

2. Executive Summary

3. Ai-Powered Breast Ultrasound Market Analysis and Forecast (2026–2030)

3.1. Overview

3.2. Market Dynamics

3.3. Drivers

3.3.1. Expanding Breast Cancer Screening Programmes Worldwide, Including Dense-Breast Notification Laws in a Growing Number of Jurisdictions That Route More Women Toward Supplemental Ultrasound Examinations.

3.3.2. Regulatory Clearances for AI-Enabled Detection, Diagnosis and Workflow Software from FDA, CE, NMPA and PMDA Authorities, Which Are Widening the Pool of Solutions Imaging Providers Can Adopt.

3.3.3. Persistent Radiologist and Sonographer Workload Pressure, Pushing Hospitals and Imaging Centers Toward Workflow Optimization and Automated Reporting Software That Shortens Per-Case Review Time.

3.3.4. Growing Adoption of Cloud-Connected and Subscription-Based AI Software Models, Which Lower the Upfront Capital Barrier for Independent Imaging Centers and Regional Health Systems.

3.4. Restraints

3.4.1. Reimbursement Pathways for AI-Assisted Breast Ultrasound Interpretation Remain Uneven Across Countries, Which Slows Purchasing Decisions at Budget-Constrained Providers.

3.4.2. Data Privacy and Cybersecurity Requirements for Cloud-Based AI Platforms Add Compliance Overhead That Can Lengthen Hospital Procurement Cycles.

3.4.3. Multiple Overlapping Regulatory Approval Pathways (FDA, CE, NMPA, PMDA and Other National Frameworks) Require Vendors to Pursue Separate Certification Efforts Before Entering Each Market.

3.5. Opportunities

3.5.1. Underserved Screening Populations in Emerging Markets, Where Portable and Handheld AI-Enabled Systems Can Extend Breast Ultrasound Access Beyond Fixed Imaging Centers.

3.5.2. Integration of Breast Density Assessment and Risk Prediction Software into Standard Screening Workflows, Opening a New Software Attach-Rate Opportunity Alongside Existing Hardware Installations.

3.5.3. Imaging-as-a-Service and Enterprise Imaging Contract Models, Which Give Ambulatory Care Centers and Academic Research Institutions a Lower-Friction Path to AI-Enabled Capability.

3.6. Porter's Five Forces Model

3.7. Value Chain Analysis

4. Product Type

4.1. Automated Breast Ultrasound Systems (ABUS)

4.2. Handheld AI-Enabled Breast Ultrasound Systems

4.3. Cart-Based AI Breast Ultrasound Platforms

4.4. Portable Breast Ultrasound Systems

4.5. Cloud-Connected Breast Ultrasound Solutions

5. AI Functionality

5.1. Computer-Aided Detection (CADe)

5.2. Computer-Aided Diagnosis (CADx)

5.3. Lesion Segmentation Algorithms

5.4. Breast Density Assessment Software

5.5. Risk Prediction Algorithms

5.6. Workflow Optimization Software

5.7. Automated Reporting Solutions

6. Imaging Workflow

6.1. Screening Applications

6.2. Diagnostic Applications

6.3. Follow-Up Monitoring

6.4. Treatment Response Assessment

6.5. Interventional Guidance

7. Technology Architecture

7.1. Embedded AI Systems

7.2. Cloud-Based AI Platforms

7.3. Hybrid AI Deployment Models

8. End User

8.1. Hospitals

8.2. Cancer Centers

8.3. Women's Health Clinics

8.4. Diagnostic Imaging Centers

8.5. Ambulatory Care Centers

8.6. Academic Research Institutions

9. Breast Density Category

9.1. Dense Breast Screening

9.2. Non-Dense Breast Screening

9.3. High-Risk Population Screening

10. Patient Age Group

10.1. Below 40 Years

10.2. 40-49 Years

10.3. 50-64 Years

10.4. 65+ Years

11. Procurement Model

11.1. Direct Equipment Purchase

11.2. AI Software Subscription

11.3. Imaging-as-a-Service

11.4. Enterprise Imaging Contracts

12. Regulatory Classification

12.1. FDA-Cleared Solutions

12.2. CE-Marked Solutions

12.3. NMPA Approved Solutions

12.4. PMDA Approved Solutions

12.5. Other National Regulatory Approvals

13. Buyer Intelligence and Demand Landscape

13.1. Buyer Segmentation

13.1.1. Buyer Industry Mapping

13.1.2. Hospital Network Purchasing Analysis

13.1.3. Women's Health Provider Landscape

13.1.4. Cancer Screening Program Demand Assessment

13.1.5. Regional Demand Clusters

13.2. Buyer Scale Classification

13.2.1. Enterprise Hospital Networks

13.2.2. Regional Health Systems

13.2.3. Independent Imaging Centers

13.2.4. Specialty Women's Health Providers

13.3. Procurement Models and Buying Triggers

13.3.1. Procurement Models

13.3.2. Buying Triggers

13.4. Decision-Maker Mapping

13.4.1. Radiology Directors

13.4.2. Breast Imaging Specialists

13.4.3. Hospital Procurement Teams

13.4.4. Clinical Engineering Teams

13.4.5. CIO and Digital Health Teams

13.5. Commercial Analysis

13.5.1. Budget Ownership Analysis

13.5.2. Vendor Evaluation Criteria

13.5.3. Contract Value Bands

13.5.4. Sales Cycle Analysis

13.6. Strategic Implications for CHISON

13.6.1. Strategic Implications for CHISON

14. By Region

14.1. North America

14.2. Europe

14.3. Asia-Pacific

14.4. Latin America

14.5. Middle East and Africa

15. North America AI-Powered Breast Ultrasound Market - Global View with Spotlight on Product Types, AI Functionality, Imaging Workflow, Technology Architecture, End Users, Breast Density and Patient Age Categories, Procurement Models, Regulatory Classification, Buyer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis Market Analysis and Forecast (2026–2030)

15.1. Introduction

15.2. Market Share Analysis

15.3. Market Size and Forecast

15.4. Market Size and Forecast, By Geography

15.4.1. United States

15.4.1.1. Market Share Analysis

15.4.1.2. Market Size and Forecast

15.4.1.3. By Product

15.4.1.4. By Technology

15.4.1.5. By Application

15.4.1.6. By Customer

15.4.2. Canada

15.4.2.1. Market Share Analysis

15.4.2.2. Market Size and Forecast

15.4.2.3. By Product

15.4.2.4. By Technology

15.4.2.5. By Application

15.4.2.6. By Customer

16. Europe AI-Powered Breast Ultrasound Market - Global View with Spotlight on Product Types, AI Functionality, Imaging Workflow, Technology Architecture, End Users, Breast Density and Patient Age Categories, Procurement Models, Regulatory Classification, Buyer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis Market Analysis and Forecast (2026–2030)

16.1. Introduction

16.2. Market Share Analysis

16.3. Market Size and Forecast

16.4. Market Size and Forecast, By Geography

16.4.1. Germany

16.4.1.1. Market Share Analysis

16.4.1.2. Market Size and Forecast

16.4.1.3. By Product

16.4.1.4. By Technology

16.4.1.5. By Application

16.4.1.6. By Customer

16.4.2. United Kingdom

16.4.2.1. Market Share Analysis

16.4.2.2. Market Size and Forecast

16.4.2.3. By Product

16.4.2.4. By Technology

16.4.2.5. By Application

16.4.2.6. By Customer

16.4.3. France

16.4.3.1. Market Share Analysis

16.4.3.2. Market Size and Forecast

16.4.3.3. By Product

16.4.3.4. By Technology

16.4.3.5. By Application

16.4.3.6. By Customer

16.4.4. Italy

16.4.4.1. Market Share Analysis

16.4.4.2. Market Size and Forecast

16.4.4.3. By Product

16.4.4.4. By Technology

16.4.4.5. By Application

16.4.4.6. By Customer

16.4.5. Spain

16.4.5.1. Market Share Analysis

16.4.5.2. Market Size and Forecast

16.4.5.3. By Product

16.4.5.4. By Technology

16.4.5.5. By Application

16.4.5.6. By Customer

16.4.6. Netherlands

16.4.6.1. Market Share Analysis

16.4.6.2. Market Size and Forecast

16.4.6.3. By Product

16.4.6.4. By Technology

16.4.6.5. By Application

16.4.6.6. By Customer

17. Asia-Pacific AI-Powered Breast Ultrasound Market - Global View with Spotlight on Product Types, AI Functionality, Imaging Workflow, Technology Architecture, End Users, Breast Density and Patient Age Categories, Procurement Models, Regulatory Classification, Buyer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis Market Analysis and Forecast (2026–2030)

17.1. Introduction

17.2. Market Share Analysis

17.3. Market Size and Forecast

17.4. Market Size and Forecast, By Geography

17.4.1. China

17.4.1.1. Market Share Analysis

17.4.1.2. Market Size and Forecast

17.4.1.3. By Product

17.4.1.4. By Technology

17.4.1.5. By Application

17.4.1.6. By Customer

17.4.2. Japan

17.4.2.1. Market Share Analysis

17.4.2.2. Market Size and Forecast

17.4.2.3. By Product

17.4.2.4. By Technology

17.4.2.5. By Application

17.4.2.6. By Customer

17.4.3. South Korea

17.4.3.1. Market Share Analysis

17.4.3.2. Market Size and Forecast

17.4.3.3. By Product

17.4.3.4. By Technology

17.4.3.5. By Application

17.4.3.6. By Customer

17.4.4. India

17.4.4.1. Market Share Analysis

17.4.4.2. Market Size and Forecast

17.4.4.3. By Product

17.4.4.4. By Technology

17.4.4.5. By Application

17.4.4.6. By Customer

17.4.5. Australia

17.4.5.1. Market Share Analysis

17.4.5.2. Market Size and Forecast

17.4.5.3. By Product

17.4.5.4. By Technology

17.4.5.5. By Application

17.4.5.6. By Customer

18. Latin America AI-Powered Breast Ultrasound Market - Global View with Spotlight on Product Types, AI Functionality, Imaging Workflow, Technology Architecture, End Users, Breast Density and Patient Age Categories, Procurement Models, Regulatory Classification, Buyer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis Market Analysis and Forecast (2026–2030)

18.1. Introduction

18.2. Market Share Analysis

18.3. Market Size and Forecast

18.4. Market Size and Forecast, By Geography

18.4.1. Brazil

18.4.1.1. Market Share Analysis

18.4.1.2. Market Size and Forecast

18.4.1.3. By Product

18.4.1.4. By Technology

18.4.1.5. By Application

18.4.1.6. By Customer

18.4.2. Mexico

18.4.2.1. Market Share Analysis

18.4.2.2. Market Size and Forecast

18.4.2.3. By Product

18.4.2.4. By Technology

18.4.2.5. By Application

18.4.2.6. By Customer

18.4.3. Argentina

18.4.3.1. Market Share Analysis

18.4.3.2. Market Size and Forecast

18.4.3.3. By Product

18.4.3.4. By Technology

18.4.3.5. By Application

18.4.3.6. By Customer

19. Middle East and Africa AI-Powered Breast Ultrasound Market - Global View with Spotlight on Product Types, AI Functionality, Imaging Workflow, Technology Architecture, End Users, Breast Density and Patient Age Categories, Procurement Models, Regulatory Classification, Buyer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis Market Analysis and Forecast (2026–2030)

19.1. Introduction

19.2. Market Share Analysis

19.3. Market Size and Forecast

19.4. Market Size and Forecast, By Geography

19.4.1. Saudi Arabia

19.4.1.1. Market Share Analysis

19.4.1.2. Market Size and Forecast

19.4.1.3. By Product

19.4.1.4. By Technology

19.4.1.5. By Application

19.4.1.6. By Customer

19.4.2. United Arab Emirates

19.4.2.1. Market Share Analysis

19.4.2.2. Market Size and Forecast

19.4.2.3. By Product

19.4.2.4. By Technology

19.4.2.5. By Application

19.4.2.6. By Customer

19.4.3. South Africa

19.4.3.1. Market Share Analysis

19.4.3.2. Market Size and Forecast

19.4.3.3. By Product

19.4.3.4. By Technology

19.4.3.5. By Application

19.4.3.6. By Customer

19.4.4. Egypt

19.4.4.1. Market Share Analysis

19.4.4.2. Market Size and Forecast

19.4.4.3. By Product

19.4.4.4. By Technology

19.4.4.5. By Application

19.4.4.6. By Customer

20. Competition Analysis

20.1. Market Positioning Overview

20.1.1. Global vs Regional Positioning

20.1.2. Value Proposition Comparison

20.1.3. Technology Differentiation Assessment

20.1.4. AI Capability Benchmarking

20.1.5. Women's Health Imaging Positioning

20.2. Competitive Benchmarking Metrics

20.2.1. Market Share Analysis

20.2.2. Pricing Tier Comparison

20.2.3. Distribution Reach Assessment

20.2.4. Service Infrastructure Benchmarking

20.2.5. Installed Base Comparison

20.2.6. Regulatory Approval Benchmarking

20.2.7. Innovation and Clinical Validation Benchmarking

20.3. Strategic Moves

20.3.1. Product Launches

20.3.2. AI Platform Partnerships

20.3.3. Imaging Software Collaborations

20.3.4. Geographic Expansion Activities

20.3.5. Investments and Funding

20.3.6. Acquisitions and Strategic Alliances

20.4. Competitive Mapping & Gaps

20.4.1. Technology White Space Analysis

20.4.2. Underserved Market Opportunities

20.4.3. AI Workflow Gap Assessment

20.4.4. Emerging Market Penetration Opportunities

20.4.5. Differentiation Opportunities for CHISON

21. Company Profiles

21.1. CHISON

21.1.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.1.2. Geographic Footprint

21.1.3. Product and Service Portfolio

21.1.4. Target Customer Segments

21.1.5. Distribution and GTM Strategy

21.1.6. Key Financials

21.1.7. Certifications and Regulatory Approvals

21.1.8. Partnerships and Alliances

21.1.9. R&D and Innovation Strategy

21.1.10. Recent Developments

21.1.11. SWOT Snapshot

21.2. GE HealthCare

21.2.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.2.2. Geographic Footprint

21.2.3. Product and Service Portfolio

21.2.4. Target Customer Segments

21.2.5. Distribution and GTM Strategy

21.2.6. Key Financials

21.2.7. Certifications and Regulatory Approvals

21.2.8. Partnerships and Alliances

21.2.9. R&D and Innovation Strategy

21.2.10. Recent Developments

21.2.11. SWOT Snapshot

21.3. Siemens Healthineers

21.3.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.3.2. Geographic Footprint

21.3.3. Product and Service Portfolio

21.3.4. Target Customer Segments

21.3.5. Distribution and GTM Strategy

21.3.6. Key Financials

21.3.7. Certifications and Regulatory Approvals

21.3.8. Partnerships and Alliances

21.3.9. R&D and Innovation Strategy

21.3.10. Recent Developments

21.3.11. SWOT Snapshot

21.4. Philips

21.4.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.4.2. Geographic Footprint

21.4.3. Product and Service Portfolio

21.4.4. Target Customer Segments

21.4.5. Distribution and GTM Strategy

21.4.6. Key Financials

21.4.7. Certifications and Regulatory Approvals

21.4.8. Partnerships and Alliances

21.4.9. R&D and Innovation Strategy

21.4.10. Recent Developments

21.4.11. SWOT Snapshot

21.5. Canon Medical Systems

21.5.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.5.2. Geographic Footprint

21.5.3. Product and Service Portfolio

21.5.4. Target Customer Segments

21.5.5. Distribution and GTM Strategy

21.5.6. Key Financials

21.5.7. Certifications and Regulatory Approvals

21.5.8. Partnerships and Alliances

21.5.9. R&D and Innovation Strategy

21.5.10. Recent Developments

21.5.11. SWOT Snapshot

21.6. FUJIFILM Healthcare

21.6.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.6.2. Geographic Footprint

21.6.3. Product and Service Portfolio

21.6.4. Target Customer Segments

21.6.5. Distribution and GTM Strategy

21.6.6. Key Financials

21.6.7. Certifications and Regulatory Approvals

21.6.8. Partnerships and Alliances

21.6.9. R&D and Innovation Strategy

21.6.10. Recent Developments

21.6.11. SWOT Snapshot

21.7. Samsung Medison

21.7.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.7.2. Geographic Footprint

21.7.3. Product and Service Portfolio

21.7.4. Target Customer Segments

21.7.5. Distribution and GTM Strategy

21.7.6. Key Financials

21.7.7. Certifications and Regulatory Approvals

21.7.8. Partnerships and Alliances

21.7.9. R&D and Innovation Strategy

21.7.10. Recent Developments

21.7.11. SWOT Snapshot

21.8. Hologic

21.8.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.8.2. Geographic Footprint

21.8.3. Product and Service Portfolio

21.8.4. Target Customer Segments

21.8.5. Distribution and GTM Strategy

21.8.6. Key Financials

21.8.7. Certifications and Regulatory Approvals

21.8.8. Partnerships and Alliances

21.8.9. R&D and Innovation Strategy

21.8.10. Recent Developments

21.8.11. SWOT Snapshot

21.9. Delphinus Medical Technologies

21.9.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.9.2. Geographic Footprint

21.9.3. Product and Service Portfolio

21.9.4. Target Customer Segments

21.9.5. Distribution and GTM Strategy

21.9.6. Key Financials

21.9.7. Certifications and Regulatory Approvals

21.9.8. Partnerships and Alliances

21.9.9. R&D and Innovation Strategy

21.9.10. Recent Developments

21.9.11. SWOT Snapshot

21.10. iSono Health

21.10.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.10.2. Geographic Footprint

21.10.3. Product and Service Portfolio

21.10.4. Target Customer Segments

21.10.5. Distribution and GTM Strategy

21.10.6. Key Financials

21.10.7. Certifications and Regulatory Approvals

21.10.8. Partnerships and Alliances

21.10.9. R&D and Innovation Strategy

21.10.10. Recent Developments

21.10.11. SWOT Snapshot

21.11. QView Medical

21.11.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.11.2. Geographic Footprint

21.11.3. Product and Service Portfolio

21.11.4. Target Customer Segments

21.11.5. Distribution and GTM Strategy

21.11.6. Key Financials

21.11.7. Certifications and Regulatory Approvals

21.11.8. Partnerships and Alliances

21.11.9. R&D and Innovation Strategy

21.11.10. Recent Developments

21.11.11. SWOT Snapshot

21.12. Koios Medical

21.12.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.12.2. Geographic Footprint

21.12.3. Product and Service Portfolio

21.12.4. Target Customer Segments

21.12.5. Distribution and GTM Strategy

21.12.6. Key Financials

21.12.7. Certifications and Regulatory Approvals

21.12.8. Partnerships and Alliances

21.12.9. R&D and Innovation Strategy

21.12.10. Recent Developments

21.12.11. SWOT Snapshot

21.13. ScreenPoint Medical

21.13.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.13.2. Geographic Footprint

21.13.3. Product and Service Portfolio

21.13.4. Target Customer Segments

21.13.5. Distribution and GTM Strategy

21.13.6. Key Financials

21.13.7. Certifications and Regulatory Approvals

21.13.8. Partnerships and Alliances

21.13.9. R&D and Innovation Strategy

21.13.10. Recent Developments

21.13.11. SWOT Snapshot

21.14. DeepHealth

21.14.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.14.2. Geographic Footprint

21.14.3. Product and Service Portfolio

21.14.4. Target Customer Segments

21.14.5. Distribution and GTM Strategy

21.14.6. Key Financials

21.14.7. Certifications and Regulatory Approvals

21.14.8. Partnerships and Alliances

21.14.9. R&D and Innovation Strategy

21.14.10. Recent Developments

21.14.11. SWOT Snapshot

21.15. Clarius

21.15.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.15.2. Geographic Footprint

21.15.3. Product and Service Portfolio

21.15.4. Target Customer Segments

21.15.5. Distribution and GTM Strategy

21.15.6. Key Financials

21.15.7. Certifications and Regulatory Approvals

21.15.8. Partnerships and Alliances

21.15.9. R&D and Innovation Strategy

21.15.10. Recent Developments

21.15.11. SWOT Snapshot

21.16. Butterfly Network

21.16.1. Overview (HQ, Ownership, Founding Year, Workforce Estimate)

21.16.2. Geographic Footprint

21.16.3. Product and Service Portfolio

21.16.4. Target Customer Segments

21.16.5. Distribution and GTM Strategy

21.16.6. Key Financials

21.16.7. Certifications and Regulatory Approvals

21.16.8. Partnerships and Alliances

21.16.9. R&D and Innovation Strategy

21.16.10. Recent Developments

21.16.11. SWOT Snapshot

Frequently Asked Questions

The market is estimated at approximately USD 3.3 Billion in 2025 and is projected to reach approximately USD 6.2 Billion by 2030, expanding at a compound annual growth rate of roughly 13.5 percent.

A category of imaging hardware and diagnostic software, spanning automated, handheld, cart-based, portable, and cloud-connected breast ultrasound systems that incorporate artificial intelligence functionality. This report describes the category strictly as a market segment.

Automated breast ultrasound systems (ABUS) account for the largest product type category by revenue, while handheld AI-enabled breast ultrasound systems form the fastest-growing product type category.

Seven categories: computer-aided detection (CADe), computer-aided diagnosis (CADx), lesion segmentation algorithms, breast density assessment software, risk prediction algorithms, workflow optimization software, and automated reporting solutions.

North America accounts for the largest regional concentration, while Asia-Pacific is the fastest-growing region, tied to hospital network expansion and rising screening programme investment.

Sixteen companies are covered in the full report, including CHISON, GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems, FUJIFILM Healthcare, Samsung Medison, Hologic, and several dedicated AI breast imaging software specialists.

Four models: direct equipment purchase, AI software subscription, imaging-as-a-service, and enterprise imaging contracts. Direct equipment purchase accounts for the largest installed base, while AI software subscription is the fastest-growing model.

Five categories: FDA-cleared, CE-marked, NMPA approved, PMDA approved, and other national regulatory approvals, each named in this report strictly as a market-access category.

No. This report describes AI-powered breast ultrasound strictly as a market and product category. It makes no claim about diagnostic accuracy, clinical effectiveness, or comparative performance for any product, software function, or company.

Inquire Before Buying Request Free Sample Ask For Discount

AI-powered breast ultrasound separated from the broader breast imaging market

AI-powered breast ultrasound is frequently reported inside the much larger breast imaging market, which spans mammography systems, breast MRI, biopsy devices, and general imaging accessories not comparable with the activity described here. A widely cited estimate for that broader category places global breast imaging at approximately USD 4.4 Billion in 2023, reaching approximately USD 6.6 Billion by 2028 at roughly an 8.5 percent CAGR. This report's estimate covers AI-powered breast ultrasound hardware, software, and platforms only, and that boundary is stated so the figure is not mistaken for the broader breast imaging category.

Derivation from automated breast ultrasound system (ABUS) published estimates

Automated breast ultrasound systems are tracked as a named category by independent research providers, giving this report a closer scope match than the broader breast imaging category above. One published estimate places the automated breast ultrasound system category at approximately USD 2.08 Billion in 2024, reaching approximately USD 6.99 Billion by 2034 at approximately a 12.9 percent CAGR. Interpolating that trajectory to this report's own 2025 and 2030 base years produces an ABUS-specific range of approximately USD 2.3 to 2.4 Billion in 2025, rising to approximately USD 4.2 to 4.3 Billion by 2030.

Broadened beyond ABUS hardware to the full AI-powered breast ultrasound scope

This report's scope is wider than automated breast ultrasound systems alone, adding handheld AI-enabled, cart-based AI, portable, and cloud-connected breast ultrasound systems, together with a standalone AI software layer, computer-aided detection, computer-aided diagnosis, lesion segmentation, breast density assessment, risk prediction, workflow optimization, and automated reporting software, sold through AI software subscription and imaging-as-a-service procurement models that ABUS-specific hardware sizing does not fully capture. A broadening adjustment of approximately 1.4 times the ABUS-only base was applied to reflect this additional product and software scope, producing a 2025 base of approximately USD 3.3 Billion.

Forecast basis and its principal sensitivity

The forecast to 2030 assumes continued global expansion of breast cancer screening programmes, continued growth in the number of jurisdictions with dense-breast notification requirements, and sustained FDA, CE, NMPA, and PMDA regulatory clearance activity for AI-enabled detection, diagnosis, and workflow software. A forward rate of approximately 13.5 percent CAGR was adopted, modestly above the ABUS-only hardware rate of 12.9 percent, reflecting the faster growth generally attributed to the AI software and subscription layer relative to hardware alone. Reimbursement policy for AI-assisted breast ultrasound interpretation is the principal sensitivity behind this trajectory.

Frequently Asked Questions

The market is estimated at approximately USD 3.3 Billion in 2025 and is projected to reach approximately USD 6.2 Billion by 2030, expanding at a compound annual growth rate of roughly 13.5 percent.

A category of imaging hardware and diagnostic software, spanning automated, handheld, cart-based, portable, and cloud-connected breast ultrasound systems that incorporate artificial intelligence functionality. This report describes the category strictly as a market segment.

Automated breast ultrasound systems (ABUS) account for the largest product type category by revenue, while handheld AI-enabled breast ultrasound systems form the fastest-growing product type category.

Seven categories: computer-aided detection (CADe), computer-aided diagnosis (CADx), lesion segmentation algorithms, breast density assessment software, risk prediction algorithms, workflow optimization software, and automated reporting solutions.

North America accounts for the largest regional concentration, while Asia-Pacific is the fastest-growing region, tied to hospital network expansion and rising screening programme investment.

Sixteen companies are covered in the full report, including CHISON, GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems, FUJIFILM Healthcare, Samsung Medison, Hologic, and several dedicated AI breast imaging software specialists.

Four models: direct equipment purchase, AI software subscription, imaging-as-a-service, and enterprise imaging contracts. Direct equipment purchase accounts for the largest installed base, while AI software subscription is the fastest-growing model.

Five categories: FDA-cleared, CE-marked, NMPA approved, PMDA approved, and other national regulatory approvals, each named in this report strictly as a market-access category.

No. This report describes AI-powered breast ultrasound strictly as a market and product category. It makes no claim about diagnostic accuracy, clinical effectiveness, or comparative performance for any product, software function, or company.

Inquire Before Buying Request Free Sample Ask For Discount